Reuters
04 Jun 2026, 18:40 UTC · 1w ago
Otsuka says kidney disease drug preserves function in late-stage study
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
04 Jun 2026, 18:40 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Otsuka Pharmaceutical's drug preserved kidney function over 12 months in a late-stage study for a specific autoimmune disease. — Positive late-stage clinical results significantly increase the probability of regulatory approval and future revenue streams for the company.
+0.60Which stocks this story touches
The company reported positive results from a late-stage study showing its drug preserved kidney function in patients.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
14h ago
